Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

mTOR Inhibition Alleviates L-DOPA-Induced Dyskinesia in Parkinsonian Rats

In English

Författare

Summary, in English

The development of dyskinesia upon chronic L-DOPA treatment is a major complication for the management of the motor symptoms in Parkinson's disease (PD) patients. Efforts are made to understand the underlying mechanisms and identify targets for the pharmacological alleviation of dyskinesia without affecting the therapeutic effect of L-DOPA. Previous studies have shown that the mTOR pathway is hyperactive in dyskinesia as a consequence of D1 receptor hypersensitivity. We investigated the effect of the FDA-approved mTOR inhibitor Temsirolimus (CCI-779), currently used in the clinic, on the development of LID and on the severity of already established LID in hemi-parkinsonian rats. Systemic delivery of CCI-779 prevented the development of LID and significantly alleviated the severity of dyskinesia in L-DOPA-primed animals. This was associated with a reduced activation of the mTOR pathway in striatal medium spiny neurons. Drugs with mTOR inhibiting activity that are actively developed in cancer research may be of interest for the management of LID in PD patients.

Publiceringsår

2013

Språk

Engelska

Sidor

13-17

Publikation/Tidskrift/Serie

Journal of Parkinson's Disease

Volym

3

Issue

1

Dokumenttyp

Artikel i tidskrift

Förlag

IOS Press

Ämne

  • Neurology

Nyckelord

  • mTOR inhibition
  • dyskinesia
  • Parkinson's disease

Status

Published

Forskningsgrupp

  • Neurobiology

ISBN/ISSN/Övrigt

  • ISSN: 1877-718X